“The standard of care we offer is critical to our patients’ childbirth experience. This new device gives us the ability to accurately deliver the proper dose of cervical ripening agent without discomfort and variability of our current method of treatment.”
Harsh Adhyaru, MD, OB/GYN
References:
- Martin JA, Hamilton BE, Osterman M, et al. Births : final data for 2016. Nat Vital stat Rep. 2018;67:1-55. Grobman WA, Rice MM, Reddy UM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network. Labor induction versus expectant management in low-risk nulliparous women. Nengl J Med.2018;379:513-523.
- ACOG Practice bulletin #107 Induction of Labor August 2099, reaffirmed 2019.
- Hofmeyr GJ, Gulmezoglu AM. Vaginal misoprostol for cervical ripening and induction of labor. Cochrane database of systemic reviews 2003 Issue1. Art No:CD000941 DOI: 10.1002
- Gregson S, Waterstone M, Norman I, Muerrells T. A randomized control trial comparing low dose vaginal misoprostol and dinoprostone vaginal gel for inducing labor at term. BJOG 2005; 112:438-44
- Garry D, Figueroa R, Kailash RB, Catalono CJ, Maulik D. Randomized control trial of vaginal misoprostol versus dinoprostone vaginal insert for induction of labor. J Maternal Fetal Neonatal Med 2003;13:254-9
- ACOG Practice Bulletin # 183 Postpartum Hemorrhage: October 2017 , reaffirmed 2019.